Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADYX OTCMKTS:AFFY OTCMKTS:ANTH OTCMKTS:PHMMF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADYXAlliqua BioMedical$0.00$0.00▼$0.00N/A2.16N/AN/AAFFYAffymax$0.00$0.00$0.00▼$0.00N/A7.59610 shsN/AANTHAnthera Pharmaceuticals$0.00$0.00▼$0.00N/A1.778,012 shs27 shsPHMMFPharma Mar$96.69$93.96$44.90▼$105.60N/A0.21,074 shsN/ATen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADYXAlliqua BioMedical0.00%0.00%0.00%0.00%0.00%AFFYAffymax0.00%0.00%0.00%0.00%+14.29%ANTHAnthera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%PHMMFPharma Mar0.00%0.00%+4.45%+0.51%+182.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APHMMFPharma MarN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADYXAlliqua BioMedical 0.00N/AN/AN/AAFFYAffymax 0.00N/AN/AN/AANTHAnthera Pharmaceuticals 0.00N/AN/AN/APHMMFPharma Mar 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADYXAlliqua BioMedicalN/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/AN/APHMMFPharma Mar$189.23MN/A$0.41 per share233.45$11.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADYXAlliqua BioMedicalN/AN/A0.00N/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/A0.00∞N/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/APHMMFPharma Mar$28.27MN/A0.00∞N/AN/AN/AN/A10/27/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADYXAlliqua BioMedicalN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/AN/AN/AN/APHMMFPharma MarN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADYXAlliqua BioMedicalN/AN/AN/AAFFYAffymaxN/AN/AN/AANTHAnthera PharmaceuticalsN/AN/AN/APHMMFPharma Mar0.202.972.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADYXAlliqua BioMedicalN/AAFFYAffymaxN/AANTHAnthera PharmaceuticalsN/APHMMFPharma MarN/AInsider OwnershipCompanyInsider OwnershipADYXAlliqua BioMedical17.40%AFFYAffymax1.55%ANTHAnthera Pharmaceuticals2.08%PHMMFPharma Mar1.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADYXAlliqua BioMedical6830,000N/ANot OptionableAFFYAffymax4N/AN/ANot OptionableANTHAnthera Pharmaceuticals20N/AN/ANot OptionablePHMMFPharma Mar509N/AN/ANot OptionablePHMMF, AFFY, ADYX, and ANTH HeadlinesRecent News About These CompaniesEuropean Growth Stocks With High Insider Ownership For August 2025August 6, 2025 | finance.yahoo.comPharma Mar SA Reports Strong H1 2025 PerformanceAugust 4, 2025 | tipranks.comPharma Mar’s Strategic Shareholder MeetingJune 18, 2025 | tipranks.comASCO 25: Jazz, PharmaMar reveal SCLC survival dataMay 26, 2025 | pharmaphorum.comPExploring High Growth Tech Stocks In Europe May 2025May 16, 2025 | finance.yahoo.comPositive Phase IIa dose-ranging study for PharmaMar’s SYL1801May 13, 2025 | thepharmaletter.comTExploring High Growth Tech Stocks in Europe April 2025April 14, 2025 | finance.yahoo.comPharma Mar’s Credit Rating Maintained at ‘BB+’April 4, 2025 | tipranks.comPharma Mar Implements Share Delivery Plan to Boost Employee EngagementApril 2, 2025 | tipranks.com3 European Growth Stocks With Insider Ownership Seeing Up To 52% Earnings GrowthMarch 27, 2025 | finance.yahoo.comPharma Mar Releases 2024 Director Remuneration ReportFebruary 28, 2025 | tipranks.comHigh Insider Ownership Growth Companies To Watch In February 2025February 21, 2025 | finance.yahoo.comHigh Growth Tech Leads These 3 Top Stocks with PotentialFebruary 11, 2025 | finance.yahoo.comPharma Mar And 2 Other Stocks That May Be Trading Below Estimated ValueFebruary 4, 2025 | uk.finance.yahoo.com3 Growth Stocks With Insider Ownership Expecting Up To 71% Earnings GrowthJanuary 23, 2025 | finance.yahoo.com3 Stocks Estimated To Be Up To 48% Below Intrinsic ValueJanuary 6, 2025 | finance.yahoo.comInsider-Led Growth Stocks To Watch In December 2024December 25, 2024 | sg.finance.yahoo.comPharma Mar S.A. Reduces Share Capital by Canceling SharesNovember 22, 2024 | markets.businessinsider.comPharma Mar Achieves Legal Win in Aplidin CaseNovember 21, 2024 | markets.businessinsider.comPharma Mar Hits $10 Million Milestone with JanssenNovember 5, 2024 | msn.comMedia Sentiment Over TimePHMMF, AFFY, ADYX, and ANTH Company DescriptionsAlliqua BioMedical OTCMKTS:ADYXAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.Affymax OTCMKTS:AFFY$0.0008 0.00 (0.00%) As of 08/22/2025Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.Anthera Pharmaceuticals OTCMKTS:ANTHAnthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.Pharma Mar OTCMKTS:PHMMF$96.69 0.00 (0.00%) As of 08/22/2025Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access